<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04781010</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-02-01</org_study_id>
    <nct_id>NCT04781010</nct_id>
  </id_info>
  <brief_title>Characterization and Outcome of Children With Leukodystrophy: An Observational Study at Sohag University Hospital</brief_title>
  <official_title>Characterization and Outcome of Children With Leukodystrophy: An Observational Study at Sohag University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leukodystrophies are heterogeneous genetic disorders characterized by the selective&#xD;
      involvement of white matter in the central nervous system (CNS) (1, 2). Inherited&#xD;
      leukodystrophies are diseases of the myelin, including abnormal myelin development,&#xD;
      hypomyelination, or degeneration of myelin (3, 4).&#xD;
&#xD;
      Most of these disorders fall into one of three categories; lysosomal storage diseases,&#xD;
      peroxisomal disorders, and diseases caused by mitochondrial dysfunction and each&#xD;
      leukodystrophy has distinctive clinical, biochemical, pathologic, and radiologic features&#xD;
      (5).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>White matter changes in MRI</measure>
    <time_frame>2 years</time_frame>
    <description>Brain MRI of all patients will be systematically reviewed, particularly Sagittal T1, Axial T1, T2-weighted and fluid-attenuated inversion-recovery (FLAIR) sequences. Other sequences will be also reviewed if available, such as MR spectroscopy (MRS) (for mitochondrial disorders or Canavan disease to investigate abnormalities in lactate or N-acetyl aspartate (NAA) respectively), and diffusion-weighting (useful in disorders such as AARS2-related leukoencephalopathy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical changes</measure>
    <time_frame>2 years</time_frame>
    <description>Arylsulfatase A levels can be measured in the leukocytes if suspected Metachromatic Leukodystrophy.&#xD;
Galactocerebrosidase (GALC) enzyme level for Krabbe's Disease.&#xD;
Plasma VLCFAs for Adrenoleukodystrophy.&#xD;
NAA levels in the urine for Canavan's Disease.&#xD;
Beta galactosidase in leukocytes deficient in cases of infantile GM1 gangliosidosis &amp;Hexosaminidase for Tay Sachs disease.&#xD;
Plasma FSH ,LH markedly reduced in cases of 4 H (Hypomyelination, hypodontia and hypogonadotropic hypogonadism syndrome).&#xD;
Genetic testing for certain diseases</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrophysiological changes</measure>
    <time_frame>2 years</time_frame>
    <description>including nerve conduction studies and electromyography will be useful in identifying peripheral nerve involvement (e.g., in AMN, MLD, Krabbe) or myopathy with or without a neuropathy (e.g., in mitochondrial diseases) or metachromatic leukodystrophy. Moreover, electroencephalographic data will be assessed, particularly in patients with seizures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tandem mass spectrometry (MS/MS) finding</measure>
    <time_frame>2 years</time_frame>
    <description>We will obtain patients' blood samples on a Glutheric card, Acylcarnitines and amino acids will be analysed using ACQUTIY TQD Tandem quadrupole UPLC/MS/MS with apositive electrospray ionization prope according to the manufacturer's instructions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary organic acid analysis</measure>
    <time_frame>2 years</time_frame>
    <description>by GC/MS using agilent 7890 and 5975 systems. Results will be calculated in mol/mmol creatinine using acalipration curve of the organic acid of interest that will be processed under the same conditions.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Children With Leukodystrophy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI pattern in children with Leukodystrophy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include children with leukodystrophy diagnosed and followed-up at the&#xD;
        pediatric neurology clinic of Sohag University Hospital during the period of the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patients fulfilling all the following criteria will be included:&#xD;
&#xD;
               1. Age â‰¤ 18 years.&#xD;
&#xD;
               2. The presence of typical clinical, biochemical, and neuroimaging features of&#xD;
                  leukodystrophies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1- Children who have coexistent genetic disorders. 2- Children who have cerebral&#xD;
             malformations. 3- History of perinatal asphyxia. 4- History of head trauma or&#xD;
             intracranial hemorrhage. 5- Acquired CNS myelin disorders, such as multiple sclerosis&#xD;
             and related acquired demyelinating processes, infectious and post-infectious white&#xD;
             matter damage, toxic injuries and non-genetic vascular insults.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nagat Mohamed, Master</last_name>
    <phone>01093952921</phone>
    <email>ngat_mohamed_post@med.sohag.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdelraheem Abdrabu, Professor</last_name>
    <phone>01065067057</phone>
  </overall_contact_backup>
  <results_reference>
    <citation>Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, McNeill NH, Helman G, Simons C, Schmidt JL, Rizzo WB, Patterson MC, Taft RJ, Vanderver A; GLIA Consortium. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab. 2015 Apr;114(4):501-515. doi: 10.1016/j.ymgme.2014.12.434. Epub 2014 Dec 29. Review.</citation>
    <PMID>25655951</PMID>
  </results_reference>
  <results_reference>
    <citation>Berger J, Moser HW, Forss-Petter S. Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis and treatment. Curr Opin Neurol. 2001 Jun;14(3):305-12. Review.</citation>
    <PMID>11371752</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Nagat Mohamed Shehata</investigator_full_name>
    <investigator_title>assistant specialist</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

